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years) who started antipsychotic treatment during July 1, 2001 and December 31,
2003. Antipsychotic users were followed for up to six months using an intent-to-
treat approach. Extended Cox proportional hazard regression model stratified on
matched pairs based on the propensity scorewas used to evaluate the comparative
risk of death among users of typical and atypical antipsychotic agents. RESULTS:
There were 84, 162 (42, 081 atypical and 42, 081 typical) users of antipsychotic
agents in the final matched cohort. The unadjusted mortality rate was 11.12% (4,
682) for atypical users and 15.01% (6, 318) for typical users. Results of Cox regression
suggest that, typical users were more likely to die compared to atypical users
[Hazard Ratio (HR) 1.59, 95% Confidence Interval (CI) 1.52-1.66]. The extended Cox
model revealed that the risk of death was greater with typical use during the initial
40 days of treatment [40days: HR 2.00, 1.86-2.15]. The difference in risk persisted
after 40 days of typical antipsychotic use [40-180 days: HR, 1.40, 1.32-1.47].
CONCLUSIONS: The use of typical antipsychotic agents was associated with short-
term and long-term risks of mortality among elderly dual eligible beneficiaries
compared to atypical use. Given the underlying poor health status of dual eligible
beneficiaries, the study findings suggest that the use of typical agents needs to be
optimized in the vulnerable elderly population.
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OBJECTIVES: The US Food and Drug Administration (FDA) requires drug manufac-
turers to implement Risk Evaluation and Mitigation Strategies (REMS) to ensure
drug benefits outweigh their risks. REMS for opioids target abuse, misuse, addic-
tion, and overdose deaths. This study aims to identify which among these REMS-
designated risk categories contribute most to societal burden, where burden is the
product of prevalence (or rate for death) and per-event cost. This study also exam-
ines opioid diversion risk as a non-REMS secondary outcome.METHODS: Based on
systematic review and meta-analysis, we estimated opioid-related mortality and
prevalence for other outcomes. For outcomes other than death, we estimated
health care costs per occurrence as documented by the Healthcare Cost and Utili-
zation Project (HCUP) dataset. We focused on the value people place on avoiding
death, rather than on the health care resources consumed. As such, we estimated
the cost of each death using the Environmental Protection Agency’s value of a
statistical life (VSL), which reflects willingness to pay to avoid mortality risks.
RESULTS: Excluding populations at high-risk for adverse behaviors, prevalence
rateswere 6% to 38% formisuse, 6% to 15% for abuse, 0.3% to 0.4% for addiction, and
9% to 20% for diversion. Mortality varied widely, ranging from 1 to 108 per 100,000
person years. Treatment costs per occurrence were $8,300 for abuse, $7,400 for
addiction, and $10,000 for diversion. Misuse had no documented treatment costs.
EPA’s VSL is $7.9 million. CONCLUSIONS: Based on prevalence and per occurrence
health care costs, abuse and diversion pose the greatest societal burden, but these
findings require verification due in part to design differences across studies and
differences among populations investigated.
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OBJECTIVES: To comparemedical care consumption between duloxetine initiators
and pregabalin initiators among fibromyalgia patients.METHODS:Weconducted a
retrospective cohort study based on a US national commercial claims database
(20062009). Fibromyalgia patients who initiated duloxetine or pregabalin in 2008,
age 18 to 64, andmaintained continuous health insurance coverage one year before
and one year after initiation were assigned to duloxetine or pregabalin cohorts
based on their initiated agent. Patients with pill coverage of the agents over last 90
pre-initiation days, with less than 30 supply days of the agents in the follow-up
year, or with a diagnosis of depression, anxiety, DPNP, epilepsy or post-herpetic-
neuralgia before the initiation were excluded. Fibromyalgia-related medical care
consumption (inpatient, outpatient, medication utilization) was compared be-
tween the two cohorts. Bootstrapping and propensity score stratification methods
were used to adjust for distribution bias as well as cross-cohort differences in
demographics, pre-index clinical and economic characteristics, and medication
history. RESULTS: Compared to pregabalin initiators (n4,838), duloxetine initia-
tors (n  3033) had a similar mean initiation age (49 years), female percentage
(89%), percentages of patients using inpatient care (11.6% vs. 11.4%), outpatient
care (100%) andmedications (92.7% vs. 92.8%) in the pre-initiation year. During the
post-initiation year, duloxetine initiators had fewer patients using fibromyalgia-
related inpatient care (2.1% vs. 3.0%, p0.05), fibromyalgia-related outpatient care
(54.0% vs. 64.3%, p0.05), specialty outpatient care (83.7% vs. 89.4%, p0.05), opi-
oids (73.5% vs. 77.1%, p0.05), and non-steroidal anti-inflammatory drugs (38.8%
vs. 41.1%, p0.05) than pregabalin initiators did. They also had fewer inpatient
admissions (0.2 vs. 0.3, p0.05), fibromyalgia-related outpatient claims (4.7 vs. 8.3,
p0.05), specialty outpatient claims (26.1 vs. 30.4, p0.05), and opioid claims (6.0 vs.
7.4, p0.05). CONCLUSIONS: Among fibromyalgia patients, duloxetine initiators
consumed less fibromyalgia-related inpatient, outpatient, and specialty outpatient
care, and had fewer post-initiation claims for opioids.
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OBJECTIVES: Conventional (on-pump) coronary artery bypass grafting (CABG) is a
surgical procedure used to restore blood flow to the cardiacmuscle in patientswith
coronary artery disease. Recently, some have suggested that an off-pump CABG
procedure has lesser post-operative morbidity and mortality. Few studies to cor-
roborate this findinghave been conducted in the elderly population. The purpose of
this studywas to compare outcomes associatedwith on-pumpand off-pumpCABG
amongMedicare beneficiaries.METHODS:A retrospective cohort study designwas
used to analyze the 5% national sample of Medicare claims data. Elderly patients
(65 years) who underwent CABG from July 1, 2006 to June 30, 2008 were identified
using ICD-9-CM codes. Outcomes were assessed (using ICD-9-CM codes) following
CABG surgery to December 31, 2008. Outcomes included acute myocardial infarc-
tion (AMI), revascularization such as percutaneous coronary intervention (PCI),
stroke, in-hospital and all-cause mortality. Propensity scores were calculated to
predict the likelihood of each individual receiving on-pump versus off-pump CABG
surgery based on patient demographics and comorbidities (identified from January
1to June 30, 2006) which were then used to match (1:1) patients in the two groups.
Conditional logistic regression was used to compare the outcomes associated with
the two procedures. RESULTS: 2,760 patients (1,380 in each group) met the inclu-
sion criteria. Patients who underwent on-pump CABG had lower odds of in-hospi-
tal mortality (OR: 0.57; 95% CI: 0.39 – 0.83) and all-cause mortality (OR: 0.69; 95% CI:
0.56 – 0.85) as compared to off-pump CABG patients. The procedures were found to
be comparable in terms of clinical outcomes including AMI, PCI and stroke.
CONCLUSIONS: This study found that in-hospital and all-cause mortality associ-
ated with on-pump CABG was lower than off-pump CABG. Further clinical trials
need to be conducted to compare the safety of on-pump versus off-pump CABG
among elderly patients.
SB3
INCREMENTAL CLINICAL AND ECONOMIC BURDEN OF UNCONTROLLED
PARTIAL-ONSET SEIZURES IN A PRIVATELY-INSURED POPULATION
Paradis PE1, Parisé H1, Duh MS2, Bowers BW3, Faught E4
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA,
3GlaxoSmithKline, Research Triangle Park, NC, USA, 4Emory University, Atlanta, GA, USA
OBJECTIVES: To assess clinical and economic consequences attributable to loss of
seizure control in privately-insured patients with partial-onset seizures (POS).
METHODS: Health insurance claims from 58 self-insured US companies between
1999 and 2009 were analyzed. Adult patients with POS (ICD-9: 345.4x, 345.5x, or
345.7x) receiving antiepileptic drugs (AED) were selected. A retrospectivematched-
cohort design was used to classify patients into cohorts of “uncontrolled POS” (2
AED therapy changes, followed by 1 epilepsy-related inpatient/ER visit within 1
year; and  1 diagnosis of POS) and “well-controlled POS” (no AED change and no
epilepsy-related inpatient/ER visit). Patients in the well-controlled POS group were
matched 1:1 with uncontrolled POS patients via propensity score matching.
Matched cohorts were compared for healthcare resource use,morbidity, and costs.
Statistical differences between cohorts were assessed using multivariate regres-
sions, adjusted for demographics, baseline AED use, comorbidities and costs.
RESULTS: From 14,377 eligible patients, 279 with uncontrolled POS (mean
age53.4, 55.6% female) were identified and matched 1:1 with well-controlled POS
patients. Compared to the well-controlled POS group, the uncontrolled POS cohort
had significantly more hospitalizations (adjusted rate ratio [ARR] (95% confidence
interval [CI])7.01 [5.97-8.82]), longer hospital stays (ARR (95% CI)10.43 [9.69-
11.23]),more ER visits (ARR (95%CI)4.99 [4.25-5.87]), andmore frequent outpatient
visits (ARR (95% CI)1.58 [1.55-1.62]). Fractures occurred three times more often in
the uncontrolled POS group (ARR (95% CI)3.43 [2.77-4.23]), while head injuries
were twice as frequent (ARR (95%CI)2.28 [2.02-2.56]). The uncontrolled POS group
incurred nearly $15,000 increase in direct healthcare costs (adjusted cost difference
(95% CI)$14,966 [$11,695-$18,944]) versus the well-controlled group. Higher direct
costs for the uncontrolled POS group were observed consistently across prescrip-
tion drug and medical service categories. CONCLUSIONS: Uncontrolled POS was
associated with significantly higher rates of healthcare resource utilization, more
frequent occurrence of fractures and head injuries, and increased direct health
care costs.
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OBJECTIVES: In infectious disease, treatment decisions are often influenced by
concerns about antibiotic resistance, which often leads to restriction of newer
agents to sicker patients (i.e., selection bias). PSM is often used to control for this
problem in “real-world” comparisons. We examined the adequacy of PSM in a
“real-world” comparison of vancomycin versus daptomycin as treatment for com-
plicated skin and skin structure infections (cSSSI). METHODS: Using a database
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